Precision medicine’s potential relies on collective action

This week, Jamie Littlejohns, chief executive of Velsera, provides an Expert View on the importance of collaboration in unlocking the full potential of AI and precision medicine. He explores how breaking down data silos, aligning stakeholder priorities, and fostering cross-industry partnerships can accelerate innovation and improve patient outcomes.

Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. However, the next big leap—using AI to drive more precise diagnostics and treatments—remains out of reach. The industry cannot fully harness AI’s potential without access to large, high-quality clinical-omic datasets for training. Compounding this challenge, a lack of alignment among industry stakeholders is further slowing progress, preventing these technologies from making a real-world impact.

Pharmaceutical companies, researchers, clinicians, and technology developers often operate in silos, unintentionally slowing the impact of groundbreaking tools. If these barriers persist, the full promise of precision medicine—faster diagnoses, tailored therapies, and longer, healthier lives—will remain just out of reach.